TrialThe Lancet. Oncology2019

Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.

Carmen D Herling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.